Evaluating treatment recommendations for children with Burkitt's Lymphoma
Official title: Recommendations for the Treatment of Children With Burkitt's Lymphoma
Run by French Africa Pediatric Oncology Group · NCT04425421 · Data updated 2026-11-12
This study is trying to find better ways to diagnose and treat children with Burkitt's Lymphoma in Sub-Saharan Africa to improve their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 18 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | French Africa Pediatric Oncology Group Academic / other |
| Drugs / interventions | rituximab |
| Locations | 7 sites (Ouagadougou and 6 other locations) |
| Status | Recruiting |
| Started | November 1, 2020 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2030 |
| Registry record updated | March 2, 2026 |
| Trial ID | NCT04425421 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children diagnosed with Burkitt's Lymphoma, particularly those in stages I, II, or IV.
✕Probably not a fit
Patients who have previously received treatment for Burkitt's Lymphoma or have other illnesses that complicate treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study, led by the French African Pediatric Oncology Group, aims to improve the early diagnosis and treatment response evaluation for children with Burkitt's Lymphoma across at least 14 Sub-Saharan countries. It focuses on children with stage I and II disease, allowing for timely treatment adjustments, and seeks to intensify treatment for those with stage IV disease. By gathering data on treatment outcomes, the study hopes to enhance the overall management of this aggressive cancer in pediatric patients.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols and outcomes for children diagnosed with Burkitt's Lymphoma.
How similar studies have gone: Previous studies focusing on Burkitt's Lymphoma treatment have shown promise, but this specific approach of early evaluation and treatment adjustment is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment. \- Exclusion Criteria: Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.
Where it's running
-
Hopital Yalgado Ouedraogo
Ouagadougou, Burkina Faso Recruiting -
CHU de Treichville à ABIDJAN
Abidjan, Côte d’Ivoire Recruiting -
Cliniques Universitaires de Kinshasa
Kinshasa, Kinshasa City, Democratic Republic of the Congo Recruiting -
Cliniques Universitaires de Lubumbashi (CUL)
Lubumbashi, Democratic Republic of the Congo Recruiting -
HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona
Antananarivo, Madagascar Recruiting -
CHU Gabriel Touré (HGT)
Bamako, Mali Recruiting
Show 1 more location
-
Hôpital Aristide Le Dantec
Dakar, Senegal Recruiting
Study contacts
- Study coordinator: Chantal Ms BOUDA, Dr.
- Email: cgbouda@yahoo.fr
- Phone: 00(226)70 10 01 30
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma
This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.
-
CX-5461 (Pidnarulex) for aggressive B‑cell lymphomas with MYC gene changes
This trial tests whether the IV drug CX-5461 (Pidnarulex) is safe and can shrink or control aggressive B‑cell lymphomas that have MYC gene changes in adults who have already had other treatments.
-
Comparing advanced and classical immunotherapy for lymphoma treatment
This study is testing whether newer immunotherapy treatments for high-grade B cell lymphoma work better and are safer than traditional methods for adults who have already had treatment that didn't work.
-
Gene therapy for certain blood cancers
This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.
-
Zilovertamab Vedotin for Pediatric and Young Adult Cancer Patients
This study is testing a new drug called zilovertamab vedotin to see if it can help kids and young adults with certain types of cancer that haven't responded to other treatments.
-
Using CAR T cells to treat certain types of B cell lymphomas
This study is testing a new CAR T cell therapy to see if it can help adults with certain types of B cell lymphomas that haven't improved with other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.